Real-world treatment patterns of palbociclib and blood count monitoring in patients with advanced breast cancer in Japan

References

• Cancer Statistics. Cancer Information Service, National Cancer Center, Japan. National Cancer Registry, Ministry of Health, Labour and Welfare (2021). https://ganjoho.jp/reg_stat/statistics/dl/index.html
   Google Scholar
• Harvey JM , ClarkGM, OsborneCK, AllredDC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol.17(5), 1474–1481 (1999).
   PubMed Web of Science ®Google Scholar
• BQ6 . Should endocrine therapy or chemotherapy be the primary treatment for ER-positive HER2-negative metastatic/recurrent breast cancer? (2021). http://jbcs.gr.jp/guidline/2018/index/yakubutu/y2-bq-6/
   Google Scholar
• El Sayed R , ElJamal L, ElIskandarani S, KortJ, AbdelSalam M, AssiH. Endocrine and targeted therapy for hormone-receptor-positive, HER2-negative advanced breast cancer: insights to sequencing treatment and overcoming resistance based on clinical trials. Front. Oncol.9, 510 (2019).
   PubMed Web of Science ®Google Scholar
• IBRANCE® (palbociclib) tablets, for oral use 2019. Prescribing information. Pfizer, NY, USA. (2022). www.accessdata.fda.gov/drugsatfda_docs/label/2019/212436lbl.pdf
   Google Scholar
• IBRANCE® (palbociclib) tablets, for oral use 2020 [interview form]. Pfizer, Shibuya, Japan [in Japanese] (2018). www.info.pmda.go.jp/go/interview/2/672212_4291051F1022_2_1F.pdf
   Google Scholar
• Finn RS , MartinM, RugoHSet al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med.375(20), 1925–1936 (2016).
   PubMed Web of Science ®Google Scholar
• Rugo HS , FinnRS, DiérasVet al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res. Treat.174(3), 719–729 (2019).
   PubMed Web of Science ®Google Scholar
• Turner NC , RoJ, AndréFet al. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med.373(3), 209–219 (2015).
   PubMed Web of Science ®Google Scholar
• Cristofanilli M , TurnerNC, BondarenkoIet al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase III randomised controlled trial. Lancet Oncol.17(4), 425–439 (2016).
   PubMed Web of Science ®Google Scholar
• Turner NC , SlamonDJ, RoJet al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med.379(20), 1926–1936 (2018).
   PubMed Web of Science ®Google Scholar
• IBRANCE® Summary of product characteristics. Pfizer, Kent, UK (2018). www.medicines.org.uk/emc/product/4449/smpc
   Google Scholar
• Mukai H , ShimizuC, MasudaNet al. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. Int. J. Clin. Oncol.24(3), 274–287 (2019).
   PubMed Web of Science ®Google Scholar
• Masuda N , InoueK, NakamuraRet al. Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients. Int. J. Clin. Onco.l24(3), 262–273 (2019).
   PubMed Web of Science ®Google Scholar
• Pharmaceutical and Medical Devices Agency. New drugs approved in FY 2017 (2017). www.pmda.go.jp/files/000232769.pdf
   Google Scholar
• IBRANCE® (palbociclib) capsules, for oral use 2020 [package insert]: Highlights of prescribing information. Pfizer, Shibuya, Japan [in Japanese].https://pins.japic.or.jp/pdf/newPINS/00067167.pdf
   Google Scholar
• Loibl S , TurnerNC, RoJet al. Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. Oncologist22(9), 1028–1038 (2017).
   PubMed Web of Science ®Google Scholar
• Medical Data Vision Co., Ltd. Press release: updated database information 2019. [in Japanese]. www.mdv.co.jp/press/2019/detail_1201.html
   Google Scholar
• Japanese Society for Pharmacoepidemiology . Survey of Japanese databases in Japan available for clinical/pharmaco-epidemiology 2019. https://drive.google.com/file/d/1wlX96kYd-rPT_OgBRjjt-Yq1XHeL0qLN/view
   Google Scholar
• e-GOV Act on the Protection of Personal Information 2019. [in Japanese]. https://elaws.e-gov.go.jp/search/elawsSearch/elaws_search/lsg0500/detail?lawId=415AC0000000057#240
   Google Scholar
• Kish JK , WardMA, GarofaloDet al. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Res.20(1), 37 (2018).
   PubMed Web of Science ®Google Scholar
• Taylor-Stokes G , MitraD, WallerJ, GibsonK, MilliganG, IyerS. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR +/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: results from the IRIS study. Breast43, 22–27 (2019).
   PubMed Web of Science ®Google Scholar
• Llombart-Cussac A , Pérez-GarcíaJM, BelletMet al. PARSIFAL: a randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer. J. Clin. Oncol.38(Suppl. 15), 1007 (2020).
   Web of Science ®Google Scholar
• Varella L , EziokwuAS, JiaXet al. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Res. Treat.176(2), 429–434 (2019).
   PubMed Web of Science ®Google Scholar
• Demichele A , CristofanilliM, BrufskyAet al. Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR +/HER2- metastatic breast cancer patients in US real-world clinical practice. Cancer Res.80, P1-19-02 (2020).
   Web of Science ®Google Scholar
• Xi J , OzaA, ThomasSet al. Retrospective analysis of treatment patterns and effectiveness of palbociclib and subsequent regimens in metastatic breast cancer. J. Natl Compr. Canc. Netw.17(2), 141–147 (2019).
   PubMed Web of Science ®Google Scholar
• Caillet P , PulidoM, BrainEet al. PALOMAGE, a French real-world cohort of elderly women beyond age 70 with advanced breast cancer receiving palbociclib: baseline characteristics and safety evaluation. J. Clin. Oncol.39(Suppl. 15), 1012–1012 (2021).
   Web of Science ®Google Scholar
• Rugo HS , TurnerNC, FinnRSet al. Palbociclib plus endocrine therapy in older women with HR +/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur. J. Cancer101, 123–133 (2018).
   PubMed Web of Science ®Google Scholar
• Ettl J , ImSA, RoJet al. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase II and III studies. Breast Cancer Res.22(1), 27 (2020).
   PubMed Web of Science ®Google Scholar
• Verma S , BartlettCH, SchnellPet al. Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3). Oncologist21(10), 1165–1175 (2016).
   PubMed Web of Science ®Google Scholar
• Diéras V , HarbeckN, JoyAAet al. Palbociclib with letrozole in postmenopausal women with ER +/HER2- advanced breast cancer: hematologic safety analysis of the randomized PALOMA-2 trial. Oncologist24(12), 1514–1525 (2019).
   PubMed Web of Science ®Google Scholar